Capivasertib + Abiraterone for Prostate Cancer
(SNARE Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized prostate cancers that are most resistant to standard treatments. This is a phase II research study. For this study, capivasertib, the study drug, will be taken with intensified androgen deprivation drugs (iADT; abiraterone and leuprolide) prior to radical prostatectomy. This study drug treatment will be evaluated to see if it is effective in shrinking and destroying prostate cancer tumors prior to surgery and to further evaluate its safety prior to prostate cancer surgery.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications. However, you cannot take certain medications like potent inhibitors or inducers of CYP3A4, drugs that prolong the QT interval, or any medication that may interfere with abiraterone. It's best to discuss your current medications with the trial team to see if they are allowed.
What data supports the idea that Capivasertib + Abiraterone for Prostate Cancer is an effective drug?
The available research shows that Abiraterone, when used with prednisone, significantly improves survival in patients with advanced prostate cancer. It helps delay the progression of the disease and increases the time patients live without the cancer getting worse. In one study, Abiraterone was shown to extend survival by about four months in patients who had already received chemotherapy. This makes it a strong option for treating prostate cancer, especially when compared to a placebo, which is a treatment with no active drug.12345
What safety data is available for Capivasertib and Abiraterone in prostate cancer treatment?
Abiraterone acetate, marketed as Zytiga, is used in combination with prednisone or prednisolone for treating metastatic castration-resistant prostate cancer (CRPC). Clinical trials have shown it significantly prolongs overall survival and progression-free survival. The safety profile is generally acceptable, with common side effects including hypokalaemia, hypertension, fluid retention, cardiac events, and hepatotoxicity. The incidences of severe adverse events were relatively low in phase III studies. There is no specific safety data provided for Capivasertib in the provided research.12678
Is the drug Capivasertib + Abiraterone a promising treatment for prostate cancer?
Yes, the drug Capivasertib + Abiraterone is promising for prostate cancer. Abiraterone has been shown to significantly improve survival and delay disease progression in patients with advanced prostate cancer. It works by blocking enzymes needed for cancer growth, making it a valuable option for treating this type of cancer.12678
Research Team
Ryan P Kopp, MD
Principal Investigator
VA Portland Health Care System, Portland, OR
Eligibility Criteria
Men over 18 with high-risk, non-metastatic prostate cancer that's not spread beyond the prostate and has specific genetic features (PTEN loss). They should have a life expectancy of more than 10 years, be able to take oral medication, and have no severe health issues. Men must use condoms if with a partner who can bear children. Those with active hepatitis or HIV, other cancers, significant heart disease or recent major surgery aren't eligible.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Run-in
Eligible patients undergo a 4-week run-in of intensified androgen deprivation therapy (iADT)
Treatment
Participants receive 16 weeks of combined iADT with AKT inhibition (capivasertib) prior to radical prostatectomy
Surgery
Participants undergo radical prostatectomy with assessment of pathological response
Follow-up
Participants are monitored for treatment-related adverse events and surgical complications
Treatment Details
Interventions
- Abiraterone Acetate
- Capivasertib
Find a Clinic Near You
Who Is Running the Clinical Trial?
VA Office of Research and Development
Lead Sponsor